Anmelden Kostenlos registrieren

Inhibrx RPE

Was ist das RPE von Inhibrx?

RPE von Inhibrx, Inc. ist $17.481k

Was ist die Definition von RPE?

Umsatz pro Mitarbeiter (RPE) ist der Umsatz geteilt durch die Anzahl der Mitarbeiter einer Organisation.

RPE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Inhibrx

Was macht Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Unternehmen mit rpe ähnlich Inhibrx